Carmot Therapeutics Announces Completion of Acquisition by Roche
29 janv. 2024 08h00 HE
|
Carmot Therapeutics
BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living...
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
04 déc. 2023 01h00 HE
|
Carmot Therapeutics
– Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments – – Carmot will join the Roche Group as part of Roche’s Pharmaceuticals...
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes
15 nov. 2023 08h30 HE
|
Carmot Therapeutics
– Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes (T1D) – – A second mechanistic clinical trial is...
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®
15 oct. 2023 12h00 HE
|
Carmot Therapeutics
– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2...
Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996
10 oct. 2023 08h55 HE
|
Carmot Therapeutics
BERKELEY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people with...
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
26 sept. 2023 08h55 HE
|
Carmot Therapeutics
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development for the treatment of obesity and type 2 diabetes – – Phase 1b data for CT-868, a once-daily...
Carmot Therapeutics Appoints Charles W. Newton to Board of Directors
19 juil. 2023 08h30 HE
|
Carmot Therapeutics
BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today...
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
23 juin 2023 21h30 HE
|
Carmot Therapeutics
– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a favorable tolerability profile over a 4 week treatment period in overweight and obese...
Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer
06 juin 2023 08h55 HE
|
Carmot Therapeutics
BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to...
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes
25 mai 2023 16h03 HE
|
Carmot Therapeutics
– Proceeds to support development of Carmot's broad clinical-stage metabolic pipeline including two Phase 2 trials of CT-388, a once weekly, dual GLP-1/GIP receptor modulator for obese adults with and...